Tags

Type your tag names separated by a space and hit enter

Essential fatty acids in the management of impaired nerve function in diabetes.
Diabetes 1997; 46 Suppl 2:S90-3D

Abstract

Impaired conversion of linoleic acid to gamma-linolenic acid (GLA) has been demonstrated in animal diabetes and inferred from blood fatty acid profiles in human diabetes. This impairment could theoretically lead to defective nerve function because metabolites of GLA are known to be important in nerve membrane structure, nerve blood flow, and nerve conduction. Administration of GLA corrects the impaired nerve function in animal models of diabetes. Two multicenter, randomized, placebo-controlled trials in humans with diabetic neuropathy have shown significant benefits of GLA as compared with placebo in neurophysiological parameters, thermal thresholds, and clinical sensory evaluations. Further work is needed to define the place of this therapeutic approach and its interactions with other treatment modalities.

Authors+Show Affiliations

Scotia Research Institute, Kentville, Nova Scotia, Canada.

Pub Type(s)

Clinical Trial
Journal Article
Review

Language

eng

PubMed ID

9285506

Citation

Horrobin, D F.. "Essential Fatty Acids in the Management of Impaired Nerve Function in Diabetes." Diabetes, vol. 46 Suppl 2, 1997, pp. S90-3.
Horrobin DF. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes. 1997;46 Suppl 2:S90-3.
Horrobin, D. F. (1997). Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes, 46 Suppl 2, pp. S90-3.
Horrobin DF. Essential Fatty Acids in the Management of Impaired Nerve Function in Diabetes. Diabetes. 1997;46 Suppl 2:S90-3. PubMed PMID: 9285506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Essential fatty acids in the management of impaired nerve function in diabetes. A1 - Horrobin,D F, PY - 1997/9/1/pubmed PY - 1997/9/1/medline PY - 1997/9/1/entrez SP - S90 EP - 3 JF - Diabetes JO - Diabetes VL - 46 Suppl 2 N2 - Impaired conversion of linoleic acid to gamma-linolenic acid (GLA) has been demonstrated in animal diabetes and inferred from blood fatty acid profiles in human diabetes. This impairment could theoretically lead to defective nerve function because metabolites of GLA are known to be important in nerve membrane structure, nerve blood flow, and nerve conduction. Administration of GLA corrects the impaired nerve function in animal models of diabetes. Two multicenter, randomized, placebo-controlled trials in humans with diabetic neuropathy have shown significant benefits of GLA as compared with placebo in neurophysiological parameters, thermal thresholds, and clinical sensory evaluations. Further work is needed to define the place of this therapeutic approach and its interactions with other treatment modalities. SN - 0012-1797 UR - https://www.unboundmedicine.com/medline/citation/9285506/full_citation L2 - http://diabetes.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=9285506 DB - PRIME DP - Unbound Medicine ER -